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Background
The certain difficulties in a choice of HAART regime
a r i s ea tp r e s e n c ea tt h ep a t i e n tw i t hH I V - i n f e c t i o na n d
tuberculosis. Enfuvirtide (ENF) not metabolized by
enzymes of system cytochrome Ð450. It does not coop-
erate with NNRTI, PI and rifamycins and can be added
to HAART regime if the patient to accept antimycobac-
terial drugs.
Purpose of the study
Comparison of efficiency and safety of HAART regimes
with and without ENF in patients with HIV-infection
and tuberculosis.
Methods
This research was not randomized and was lead in con-
ditions of real clinical practice. 81 pts with HIV-infec-
tion and tuberculosis were divided on 2 groups: 1 gr. -
26 pt. with the standard regimes of HAART (2 NRTI +
PI/r or NNRTI) and ENF; 2 gr. - 55 pts with the stan-
dard regimes of HAART. We determined clinical symp-
toms, CD4+ lymphocyte’s count, viral load,
haematological and biochemical parameters before, 4, 12
and 24 weeks therapy.
Summary of results
Within 24 weeks HAART the survival rate of patients of
1 gr. has made 96,2%, and 2nd - 89,1%. After 24 weeks
HAART the share of pts with VL <500 copies/ml at pts
1 gr. was 81,8% and 2 gr. - 65% (OT- analysis, p <0,05)
and 76% - 50% (ITT-analysis, p <0,05). After 24 weeks
HAART the median of a gain of quantity CD4+ lym-
phocytes at pts of 1 gr. has made +110 cells, and 2 gr. -
69 cells (p <0,05). Safety of both regimes of HAART
was quite good. Only 1 pt after 12 weeks of treatment
has refused therapy with ENF because of local reactions.
Conclusions
Inclusion in regimes of HAART of ENF promoted
increase in a share of pts with not determined HIV
RNA level and to more essential growth of CD4+lym-
phocyte’s count. Addition to standard regime of
HAART of ENF essentially did not influence on the fre-
quency of the clinical or laboratory adverse events
caused by treatment.
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